{"id":1000624,"date":"2020-07-01T11:44:52","date_gmt":"2020-07-01T09:44:52","guid":{"rendered":"https:\/\/frezzapartners.com\/?p=1000624"},"modified":"2020-07-01T11:44:52","modified_gmt":"2020-07-01T09:44:52","slug":"takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali","status":"publish","type":"post","link":"https:\/\/frezzapartners.com\/en\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\/","title":{"rendered":"Takeda-Carmine Therapeutics: accordo da $900 mln per nuove terapie geniche non virali"},"content":{"rendered":"<p>photo by <a href=\"https:\/\/unsplash.com\/@randyfath?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText\">Randy Fath<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>La giapponese Takeda e l&#8217;azienda biotech americana Carmine Therapeutics hanno finalizzato un <a href=\"https:\/\/www.thepharmaletter.com\/article\/takeda-moves-further-in-to-gene-therapy-via-900-million-carmine-collaboration\">accordo<\/a> di collaborazione per lo sviluppo e la commercializzazione di terapie geniche non virali per due malattie rare.<\/p>\n<p>In particolare, Takeda riconoscer\u00e0 a Carmine un pagamento anticipato, dar\u00e0 un sostegno finanziario per la ricerca, impegnandosi a versare un prestito per sostenere lo sviluppo della piattaforma tecnologica REGENT di Carmine. Quest\u2019ultima ricever\u00e0 900 milioni di dollari in pagamenti in milestones e royalties. Takeda potr\u00e0 inoltre prendere in licenza i programmi dopo la conclusione degli studi preclinici di proof-of-concept. E portare avanti lo sviluppo clinico e la commercializzazione.<\/p>\n<p>&#8220;E&#8217; un piacere avviare questa collaborazione con Takeda, leader mondiale nelle terapie per le malattie rare, a poco pi\u00f9 di un anno dalla creazione e dall&#8217;incubazione di Carmine da parte di Esco Ventures X&#8221;, ha commentato XQ Lin, AD e fondatore di Carmine. &#8220;Questo fornisce a Carmine un significativo finanziamento per sviluppare ulteriormente la nostra piattaforma REGENT e far progredire i nostri programmi interamente di propriet\u00e0&#8221;.<\/p>\n<p>Carmine \u00e8 stata fondata nel 2019 da Esco Ventures X, Harvey Lodish con il Whitehead Institute for Biomedical Research e MIT, e i ricercatori di Singapore Minh Le e Jiahai Shi. Ad oggi la societ\u00e0 ha raccolto pi\u00f9 di 9,4 milioni di dollari in finanziamenti azionari di seed equity guidati da Esco Ventures e Takeda Ventures. Nel dicembre 2019, Carmine <a href=\"https:\/\/www.escoventures.com\/post\/carmine-therapeutics-scored-the-bristol-myers-squibb-s-2019-golden-tickets\">aveva vinto<\/a> uno dei due premi di Bristol Myers Squibb 2019 per entrare nel LabCentral, laboratorio per aziende operanti nel Life Sciences e startup biotecnologiche basato nel Massachusets.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>photo by Randy Fath &nbsp; La giapponese Takeda e l&#8217;azienda biotech americana Carmine Therapeutics hanno finalizzato un accordo di collaborazione per lo sviluppo e la commercializzazione di terapie geniche non virali per due malattie rare. In particolare, Takeda riconoscer\u00e0 a Carmine un pagamento anticipato, dar\u00e0 un sostegno finanziario per la ricerca, impegnandosi a versare un prestito per sostenere lo sviluppo della piattaforma tecnologica REGENT di Carmine. Quest\u2019ultima ricever\u00e0 900 milioni di dollari in pagamenti in milestones e royalties. Takeda potr\u00e0&#8230;<\/p>\n","protected":false},"author":297440,"featured_media":1000627,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[141],"tags":[2792,2791],"class_list":["post-1000624","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-carmine","tag-takeda"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Takeda-Carmine Therapeutics: accordo da $900 mln per nuove terapie geniche non virali - Frezza Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/frezzapartners.com\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda-Carmine Therapeutics: accordo da $900 mln per nuove terapie geniche non virali - Frezza Partners\" \/>\n<meta property=\"og:description\" content=\"photo by Randy Fath &nbsp; La giapponese Takeda e l&#8217;azienda biotech americana Carmine Therapeutics hanno finalizzato un accordo di collaborazione per lo sviluppo e la commercializzazione di terapie geniche non virali per due malattie rare. In particolare, Takeda riconoscer\u00e0 a Carmine un pagamento anticipato, dar\u00e0 un sostegno finanziario per la ricerca, impegnandosi a versare un prestito per sostenere lo sviluppo della piattaforma tecnologica REGENT di Carmine. Quest\u2019ultima ricever\u00e0 900 milioni di dollari in pagamenti in milestones e royalties. Takeda potr\u00e0...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/frezzapartners.com\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\/\" \/>\n<meta property=\"og:site_name\" content=\"Frezza Partners\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-01T09:44:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/07\/randy-fath-G1yhU1Ej-9A-unsplash-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frezza Partners\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frezza Partners\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\\\/\"},\"author\":{\"name\":\"Frezza Partners\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"headline\":\"Takeda-Carmine Therapeutics: accordo da $900 mln per nuove terapie geniche non virali\",\"datePublished\":\"2020-07-01T09:44:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\\\/\"},\"wordCount\":266,\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/randy-fath-G1yhU1Ej-9A-unsplash-scaled.jpg\",\"keywords\":[\"carmine\",\"takeda\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\\\/\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\\\/\",\"name\":\"Takeda-Carmine Therapeutics: accordo da $900 mln per nuove terapie geniche non virali - Frezza Partners\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/randy-fath-G1yhU1Ej-9A-unsplash-scaled.jpg\",\"datePublished\":\"2020-07-01T09:44:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/frezzapartners.com\\\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\\\/#primaryimage\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/randy-fath-G1yhU1Ej-9A-unsplash-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/randy-fath-G1yhU1Ej-9A-unsplash-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/frezzapartners.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Takeda-Carmine Therapeutics: accordo da $900 mln per nuove terapie geniche non virali\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/\",\"name\":\"Frezza Partners\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/frezzapartners.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\",\"name\":\"Frezza Partners\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/en\\\/author\\\/fr3zz4partn3rs\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Takeda-Carmine Therapeutics: accordo da $900 mln per nuove terapie geniche non virali - Frezza Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/frezzapartners.com\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\/","og_locale":"en_US","og_type":"article","og_title":"Takeda-Carmine Therapeutics: accordo da $900 mln per nuove terapie geniche non virali - Frezza Partners","og_description":"photo by Randy Fath &nbsp; La giapponese Takeda e l&#8217;azienda biotech americana Carmine Therapeutics hanno finalizzato un accordo di collaborazione per lo sviluppo e la commercializzazione di terapie geniche non virali per due malattie rare. In particolare, Takeda riconoscer\u00e0 a Carmine un pagamento anticipato, dar\u00e0 un sostegno finanziario per la ricerca, impegnandosi a versare un prestito per sostenere lo sviluppo della piattaforma tecnologica REGENT di Carmine. Quest\u2019ultima ricever\u00e0 900 milioni di dollari in pagamenti in milestones e royalties. Takeda potr\u00e0...","og_url":"https:\/\/frezzapartners.com\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\/","og_site_name":"Frezza Partners","article_published_time":"2020-07-01T09:44:52+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/07\/randy-fath-G1yhU1Ej-9A-unsplash-scaled.jpg","type":"image\/jpeg"}],"author":"Frezza Partners","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Frezza Partners","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/frezzapartners.com\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\/#article","isPartOf":{"@id":"https:\/\/frezzapartners.com\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\/"},"author":{"name":"Frezza Partners","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"headline":"Takeda-Carmine Therapeutics: accordo da $900 mln per nuove terapie geniche non virali","datePublished":"2020-07-01T09:44:52+00:00","mainEntityOfPage":{"@id":"https:\/\/frezzapartners.com\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\/"},"wordCount":266,"image":{"@id":"https:\/\/frezzapartners.com\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/07\/randy-fath-G1yhU1Ej-9A-unsplash-scaled.jpg","keywords":["carmine","takeda"],"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/frezzapartners.com\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\/","url":"https:\/\/frezzapartners.com\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\/","name":"Takeda-Carmine Therapeutics: accordo da $900 mln per nuove terapie geniche non virali - Frezza Partners","isPartOf":{"@id":"https:\/\/frezzapartners.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/frezzapartners.com\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\/#primaryimage"},"image":{"@id":"https:\/\/frezzapartners.com\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/07\/randy-fath-G1yhU1Ej-9A-unsplash-scaled.jpg","datePublished":"2020-07-01T09:44:52+00:00","author":{"@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"breadcrumb":{"@id":"https:\/\/frezzapartners.com\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/frezzapartners.com\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/frezzapartners.com\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\/#primaryimage","url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/07\/randy-fath-G1yhU1Ej-9A-unsplash-scaled.jpg","contentUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/07\/randy-fath-G1yhU1Ej-9A-unsplash-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/frezzapartners.com\/takeda-carmine-therapeutics-accordo-da-900-mln-per-nuove-terapie-geniche-non-virali\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/frezzapartners.com\/"},{"@type":"ListItem","position":2,"name":"Takeda-Carmine Therapeutics: accordo da $900 mln per nuove terapie geniche non virali"}]},{"@type":"WebSite","@id":"https:\/\/frezzapartners.com\/#website","url":"https:\/\/frezzapartners.com\/","name":"Frezza Partners","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/frezzapartners.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0","name":"Frezza Partners","url":"https:\/\/frezzapartners.com\/en\/author\/fr3zz4partn3rs\/"}]}},"_links":{"self":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/1000624","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/users\/297440"}],"replies":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/comments?post=1000624"}],"version-history":[{"count":0,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/1000624\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media\/1000627"}],"wp:attachment":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media?parent=1000624"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/categories?post=1000624"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/tags?post=1000624"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}